Acronym: Switching from Ticagrelor to Clopidogrel in Patients with Coronary Artery Disease
Purpose: Evaluation of the pharmacodynamic effects of switching patients with coronary artery disease from ticagrelor (Brilinta, AstraZeneca) to clopidogrel
Format: Randomized, open-label, parallel-assignment
Treatment Group: Ticagrelor 90 mg
Control Group: Clopidogrel
Number of Participants: 87
Inclusion Criteria: Patients with coronary artery disease
Summary: In all assays at all time points, ticagrelor 90 mg twice daily conferred lower platelet reactivity than any clopidogrel regimen. P2Y12 reaction unit levels did not significantly differ between those who took a clopidogrel 600-mg loading dose 24 hours after stopping ticagrelor and those who took clopidogrel 75 mg per day 24 hours after stopping ticagrelor (P = .29). P2Y12 reaction unit levels were lower in patients who took a clopidogrel 600-mg loading dose 12 hours after stopping ticagrelor vs. those who took clopidogrel 75 mg per day 24 hours after stopping ticagrelor (P = .024).
Franchi F, et al. Circulation. 2018;doi:10.1161/CIRCULATIONAHA.118.033983.